Holen Sie sich die Stockscreener-App
78.39
1.04%
0.7894
Schlusskurs vom Vortag:
$77.60
Offen:
$77.96
24-Stunden-Volumen:
271.28K
Relative Volume:
0.22
Marktkapitalisierung:
$4.02B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.99M
KGV:
-26.16
EPS:
-2.9966
Netto-Cashflow:
$-24.94M
1W Leistung:
-0.94%
1M Leistung:
+4.53%
6M Leistung:
+73.19%
1J Leistung:
+87.12%
1-Tages-Spanne:
$76.92
$79.10
1-Wochen-Bereich:
$76.14
$81.54
52-Wochen-Spanne:
$36.93
$81.54
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Firmenname
Soleno Therapeutics Inc
Sektor
Branche
Telefon
650-213-8444
Adresse
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Vergleichen Sie SLNO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
78.41 | 4.02B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.52 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
514.83 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.28 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.90 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
253.79 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2024-12-02 | Bestätigt | Robert W. Baird | Outperform |
| 2024-12-02 | Bestätigt | Stifel | Buy |
| 2024-09-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-23 | Eingeleitet | Stifel | Buy |
| 2023-11-21 | Fortgesetzt | Guggenheim | Buy |
| 2020-09-29 | Eingeleitet | Guggenheim | Buy |
| 2020-01-10 | Eingeleitet | Craig Hallum | Buy |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Soleno stock maintains Overweight rating at Piper Sandler on VYKAT XR outlook - Investing.com India
Trend Tracker for (SLNO) - news.stocktradersdaily.com
High Growth Tech Stocks in US for June 2025 - Yahoo Finance
Capnia Inc stock soars to 52-week high, hits $81.03 By Investing.com - Investing.com Nigeria
Capnia Inc stock soars to 52-week high, hits $81.03 - Investing.com
Soleno Therapeutics Insiders Sell US$39m Of Stock, Possibly Signalling Caution - simplywall.st
Transcript : Soleno Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - marketscreener.com
Soleno Therapeutics Holds Annual Stockholders Meeting - TipRanks
Transcript : Soleno Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
Trading (SLNO) With Integrated Risk Controls - news.stocktradersdaily.com
Soleno Therapeutics’ SWOT analysis: vykat xr launch propels stock amid rare disease market potential - Investing.com India
Stifel maintains Soleno Therapeutics stock Buy rating, $108 target - Investing.com
Stifel maintains Soleno Therapeutics stock Buy rating, $108 target By Investing.com - Investing.com India
EMA validates Soleno’s application for Prader-Willi syndrome treatment - Yahoo Finance
(SLNO) Trading Report - news.stocktradersdaily.com
Soleno Therapeutics seeking regulatory approval in treatment of PWS - Yahoo Finance
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Friday - marketscreener.com
Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock By Investing.com - Investing.com South Africa
Soleno Application for Hyperphagia Treatment in Patients with Prader-Willi Syndrome Gets European Validation - marketscreener.com
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR - Insider Monkey
Soleno seeks EU approval for Prader-Willi syndrome treatment - Investing.com Australia
Soleno seeks EU approval for Prader-Willi syndrome treatment By Investing.com - Investing.com Canada
Soleno Therapeutics' (SLNO) MAA for PWS Treatment Validated by EMA | SLNO Stock News - GuruFocus
Soleno Therapeutics Announces Submission and EMA Validation - GlobeNewswire
Soleno's PWS Drug VYKAT Advances in Europe After Recent FDA ApprovalKey Details for Investors - Stock Titan
BCE Inc: Stock Forecast & Analysis - The Globe and Mail
Buy AT&T or Verizon Stock if Market Volatility Resurges? - The Globe and Mail
Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock - Investing.com Australia
Soleno Therapeutics to Participate in Upcoming June Conferences - GlobeNewswire
Lowe’s Stock Uptrend Can Continue for These 2 Reasons - The Globe and Mail
Rare Disease Leader Soleno Therapeutics Secures Speaking Slots at Major Healthcare Conferences - Stock Titan
Piper Sandler maintains $145 target on Soleno Therapeutics stock - Investing.com Australia
Soleno reports positive VYKAT XR results for Prader-Willi syndrome By Investing.com - Investing.com South Africa
Piper Sandler maintains $145 target on Soleno Therapeutics stock By Investing.com - Investing.com Canada
Soleno reports positive VYKAT XR results for Prader-Willi syndrome - Investing.com Australia
Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Resu - GuruFocus
Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Results | SLNO Stock News - GuruFocus
Soleno Therapeutics Presents Positive Clinical Data for VYKAT™ XR at the 2025 Pediatric Endocrine Society Annual Meeting - Nasdaq
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants wi - The Manila Times
VYKAT XR Clinical Data Shows Major Improvements in Prader-Willi Syndrome Symptoms | SLNO Stock News - Stock Titan
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Company News for May 19, 2025 - The Globe and Mail
Northern Trust Corp Buys 34,309 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 - GlobeNewswire
Finanzdaten der Soleno Therapeutics Inc-Aktie (SLNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.59%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):